Press Release January 21, 2021

Royalty Pharma Acquires Royalty Interest in Minerva Neurosciences Seltorexant for $60 Million Upfront and up to $95 Million in Additional Milestone Payments

The Life Sciences team advised Royalty Pharma (Nasdaq: RPRX) on its acquisition of Minerva Neurosciences (Nasdaq: NERV) royalty interest in seltorexant for an upfront payment of $60 million and up to $95 million in additional milestone payments. The additional payments to Minerva will be contingent on the achievement of certain clinical, regulatory and commercialization milestones.

 

Seltorexant is currently in Phase 3 development for the treatment of major depressive disorder with insomnia symptoms by Janssen Pharmaceutica, N.V.

 

Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies.

 

The Goodwin team was led by Arthur McGivernRobert CrawfordJacqueline MercierJoseph Flynn and Alexandra Haas.

 

For additional details on the transaction, please read the press release.